These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20680964)

  • 1. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
    Subbiah IM; Brown RE; Fallon MB
    Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
    [No Abstract]   [Full Text] [Related]  

  • 2. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity.
    Sharp ZD; Strong R
    J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):580-9. PubMed ID: 20083554
    [No Abstract]   [Full Text] [Related]  

  • 4. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
    Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
    Huynh H
    Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin: the cure for all that ails.
    Hasty P
    J Mol Cell Biol; 2010 Feb; 2(1):17-9. PubMed ID: 19805415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
    BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression?
    Soll C; Clavien PA
    Hepatology; 2010 Apr; 51(4):1113-5. PubMed ID: 20373365
    [No Abstract]   [Full Text] [Related]  

  • 9. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
    Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
    Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S; Thompson JA
    Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study: rapamycin in advanced hepatocellular carcinoma.
    Schöniger-Hekele M; Müller C
    Aliment Pharmacol Ther; 2010 Sep; 32(6):763-8. PubMed ID: 20629977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Liver transplantation for hepatocellular carcinoma and potential application of PSI].
    Decaens T; Duvoux C
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
    Ji J; Zheng PS
    Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional consequences of mTOR inhibition.
    Sudarsanam S; Johnson DE
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
    Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
    Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
    BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular cancer, transplantation, and sirolimus.
    Wall WJ
    Liver Transpl; 2004 Oct; 10(10):1312-4. PubMed ID: 15376337
    [No Abstract]   [Full Text] [Related]  

  • 20. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.